Year: 2022

Tampa, Dec. 12, 2022 (GLOBE NEWSWIRE) — Star8 Corp. (OTCPK: STRH) is please to announce that the corporate headquarters has officially moved to the Tampa Urban Centre at Westshore, located at 4830 West Kennedy Blvd., Suite 600, Tampa, Florida, 33609.  The facility allows us great flexibility for meeting and the ability to expand when it become necessary.  Additionally, the headquarters is closer to Hyper 30 Data operations, which allows better control and management.  Secondly, we are activity reviewing the qualifications of number of independent auditing firms, and I expect to announce the engagement within a few days.  Completing an audit of our Company is important for two reasons, 1) to become a fully reporting entity, and 2) be up-listed OTCqb. Thirdly, our Company, through the acquisition of Hyper 30 Data is now focused on...

Building capabilities and staying at the forefront of an important energy shift London, December 12, 2022 CNH Industrial announced during its Tech Day in Phoenix, Arizona, USA, that it has opened a new technical center in the Detroit Metro area of Michigan, USA. Designed to support our growing innovation in electrification, the center will enhance CNH Industrial’s technology capabilities. This is facilitated by its proximity to a nationwide hub for electrification OEMs and suppliers. “This new location underlines our commitment to growing our electric vehicle and subsystem profile, and marks yet another milestone after successfully expanding our in-house team,” said Marc Kermisch, Chief Digital and Information Officer and ad interim Chief Technology & Quality Officer, CNH Industrial. “Under one roof our team can now leverage cross-functional...

— Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML — No evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax — ALX Oncology to Host Conference Call on December 13th at 7:30 a.m. EST SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the presentation of clinical data from the Phase 1a dose escalation part of the ASPEN-05 trial evaluating evorpacept in combination with azacitidine and venetoclax for the treatment of patients with relapsed or refractory (“r/r”) or newly diagnosed (“ND”) acute myeloid leukemia...

Keros Therapeutics will be hosting a conference call and webcast today, December 12, 2022, at 4:01 p.m. ET. LEXINGTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”), as well as initial data from its ongoing Phase 2 clinical trial of KER-050 in patients with myelofibrosis (“MF”) and from its ongoing Phase 2 clinical trial of KER-047 in patients with iron-refractory iron...

Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinical trial of CPI-818 in T cell lymphoma and a Phase 1 clinical trial in atopic dermatitis, both in 2023 Company to host conference call and webcast today at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced updated results from its Phase 1/1b trial of CPI-818, the Company’s ITK inhibitor, which demonstrated its anti-tumor activity in patients with T cell lymphoma (TCL) and its therapeutic potential in Th2...

Activity of STAT3 degrader in preclinical model of cutaneous T-cell lymphoma (CTCL) validates selective STAT3 degradation as a potential therapeutic strategy for STAT3-driven T cell malignancies Preclinical study highlights the potential of IRAKIMiDs combined with BCL-2 inhibitor as a therapeutic approach for the treatment of MYD88-mutant diffuse large B-cell lymphoma (DLBCL) WATERTOWN, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that preclinical data from collaborations for its STAT3 and IRAKIMiD degraders was presented at the American Society of Hematology (ASH) Annual Meeting, taking place from December 10 – 13, 2022 in New Orleans,...

– As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks – – No patients in this Phase 2 study of bomedemstat in advanced myelofibrosis have progressed to acute myeloid leukemia while on treatment – – The Phase 2 study of bomedemstat in advanced myelofibrosis is fully enrolled, with an investigator-sponsored Phase 2 combination study of bomedemstat and ruxolitinib in myelofibrosis currently screening patients – REDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and...

-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1 CARBON™ clinical trial- -Part A data presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition confirm that CTX110® can lead to long-term durable complete remissions (CRs) for heavily pre-treated Large B-cell Lymphoma (LBCL) patients; three patients remain in CR beyond two years- -Emerging data from Part B demonstrate the benefits of consolidation dosing with a positively differentiated safety profile consistent with Part A- -Based on discussions with regulatory agencies, the Company has initiated a Phase 2 single-arm potentially registrational trial with drug product manufactured using a commercial-ready process and specifications- ZUG, Switzerland and BOSTON, Dec. 12, 2022 (GLOBE...

Company to Host Conference Call at 4:30 PM Eastern Time FORT MYERS, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announced that the Company will release financial results for the fourth quarter and full year ended September 30, 2022, on Tuesday, December 13, after the market close. The Company will host a conference call to discuss its financial results on December 13, 2022, at 4:30 pm Eastern Time. Interested parties may join the conference call by dialing 1-877-407-0792 in the United States and 1-201-689-8263 from outside of the United States. The participant identification to join the conference call is 13734919. A telephone replay will be available on December 13, 2022, approximately two hours after the call concludes, and will be available through December 27, 2022. Listeners...